Large-scale randomised controlled trials in Europe and the United States are informing evidence-based clinical advice
Population-wide prostate-specific antigen (PSA) screening for prostate cancer is not recommended in Australia, primarily because of the lack of large-scale randomised trial evidence of a beneficial effect on prostate cancer mortality and the known harms of overdiagnosis and unnecessary treatment that may ensue. In spite of this, PSA testing is common; the limited evidence available suggests that more than 50% of Australian men over the age of 50 years have had the test.1,2
- David P Smith1
- Emily Banks2
- Mark S Clements2
- Robert A Gardiner3,4
- Bruce K Armstrong5
- 1 Cancer Epidemiology Research Unit, Cancer Council NSW, Sydney, NSW.
- 2 National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT.
- 3 University of Queensland Centre for Clinical Research, Brisbane, QLD.
- 4 Royal Brisbane and Women’s Hospital, Brisbane, QLD.
- 5 School of Public Health, University of Sydney, Sydney, NSW.
Correspondence: dsmith@nswcc.org.au
Responses are now closed for this article.